In clinical practice, it is not uncommon for autistic patients to arrive after years of treatment with a firm conclusion: Psychiatric medications do not work for them. This belief is typically built on multiple medication trials, inconsistent benefit, and often significant side effects. But the conclusion itself may be misleading. What is often being observed is not true treatment resistance, but a mismatch between standard psychopharmacology and the neurobiology of the autistic brain.

The data behind autism and psychiatric medications

Psychiatric medications do behave differently in individuals with autism spectrum disorder (ASD) compared to neurotypical populations. Across the literature, several patterns emerge. Stimulant medications, commonly used for attention-deficit/hyperactivity disorder (ADHD) symptoms, show reduced efficacy and increased adverse effects in individuals with comorbid ASD. In the Research Units on Pediatric Psychopharmacology (RUPP) Autism Network trial, methylphenidate demonstrated lower effect sizes and higher rates of adverse effects compared to typical ADHD populations.

Selective serotonin reuptake inhibitors (SSRIs), widely prescribed for anxiety, depression, and obsessive-compulsive symptoms, show limited to no benefit for core autism features in children. A large randomized controlled trial of citalopram in children with ASD (King et al., New England Journal of Medicine, 2009) found no significant improvement in repetitive behaviors compared to placebo, with notable side effects. A systematic review similarly found no evidence supporting SSRI efficacy for core symptoms and highlighted the potential for harm.

In contrast, atypical antipsychotics such as risperidone and aripiprazole demonstrate moderate to large effect sizes for irritability and aggression. Trials by the RUPP Autism Network (New England Journal of Medicine, 2002) and subsequent studies of aripiprazole (Marcus et al., Pediatrics, 2009) showed meaningful reductions in irritability, though accompanied by significant metabolic risks. Taken together, the literature reflects a pattern of lower efficacy, higher rates of adverse effects, and marked variability in response.

Why variability is the rule

One of the most clinically relevant features of medication response in autism is its unpredictability. Two patients with similar diagnoses may respond in entirely different ways to the same medication. One may benefit at a very low dose, while another experiences significant side effects with minimal therapeutic gain. This variability reflects underlying neurobiological differences, including

• altered balance in excitatory and inhibitory signaling
• differences in serotonin, dopamine, and noradrenergic systems
• variations in receptor sensitivity and downstream signaling
• pharmacogenomic differences in drug metabolism

These factors influence not only whether a medication works, but how it is tolerated.

The clinical consequence of premature treatment failure

In practice, these differences often lead to a familiar pattern. Medications are started at standard doses, titrated on typical timelines, and side effects emerge early. The medication is discontinued. This process repeats across multiple trials. Eventually, the patient concludes that medications do not work. But an important question is often overlooked: Was the medication ineffective, or was the approach mismatched?

The principle of “start low, go slow” is foundational in psychiatry. In autistic patients, it often needs to be taken further. Start very low, often a quarter of what you would normally start in a neurotypical patient. Increase very gradually. Allow sufficient time at each dose. Clinically effective doses may fall well below standard therapeutic ranges. When dosing is individualized in this way, medications previously considered intolerable may become both manageable and beneficial.

Medication performance varies across populations

Medication performance is not uniform across populations. Certain medications that demonstrate only modest response rates in neurotypical individuals may show a disproportionately favorable response in autistic patients when used thoughtfully and at appropriate dosing. This is not universal, and it is not always predictable from standard prescribing frameworks. But it is observed often enough in clinical practice to warrant attention.

Differences in underlying neurobiology can result in a medication showing limited benefit in one population and robust efficacy in another. This challenges a core assumption in psychopharmacology: that efficacy generalizes across populations. In some cases, the issue is not that the medication failed. It is that we applied the wrong expectations to the wrong brain.

The role of underlying biology in psychiatric care

Another layer that is often under-addressed in psychiatric care, particularly in autistic patients, is the contribution of underlying physiological factors. Before concluding that a medication has failed, it is worth considering whether the biological foundation required for optimal brain function is in place. Micronutrients such as vitamin D, vitamin B12, folate, iron, magnesium, and zinc play essential roles in neurotransmitter synthesis, receptor function, mitochondrial energy production, and regulation of the stress response. Consider the following examples:

• Iron is required for dopamine synthesis and is closely linked to attention and mood.
• Vitamin B12 and folate are critical for methylation pathways that influence neurotransmitter production.
• Magnesium plays a role in N-methyl-D-aspartate (NMDA) receptor modulation and nervous system regulation.
• Zinc contributes to synaptic signaling and neuroplasticity.
• Vitamin D influences gene expression, immune regulation, and brain function.

Deficiencies in these systems can alter how the brain responds to both internal and external inputs, including medications. In autistic individuals, where neurobiological sensitivity is often heightened, these factors may further influence both efficacy and tolerability. Addressing these variables does not replace pharmacologic treatment when indicated. It creates a more stable biological foundation upon which treatment can be more effective and better tolerated.

A needed shift in framework for neurodivergence

Psychiatric medications are not designed to change an individual’s underlying neurodevelopmental identity. Instead, they are used to support co-occurring symptoms such as anxiety, depression, irritability, attention differences, and sleep disturbance that may contribute to distress or functional impairment. A standardized approach may lead to poor outcomes and unnecessary side effects. An individualized approach, informed by neurobiology and careful titration, can lead to very different results.

When an autistic patient reports that medications have not worked, it may be worth reconsidering not only what was prescribed, but how. In many cases, the difference between failure and success is not the medication itself. It is the match between the treatment approach and the brain it is being used in.

The narrative that medications do not work in autism is understandable. But it may not be accurate. What we are often seeing is not the failure of the medication. It is the failure of a one-size-fits-all approach.

Carrie Friedman is a dual board-certified psychiatric and family nurse practitioner and the founder of Brain Garden Psychiatry in California. She integrates evidence-based psychopharmacology with functional and integrative psychiatry, emphasizing root-cause approaches that connect neuro-nutrition and gut–brain science, metabolic psychiatry, immunology, endocrinology, and mind–body lifestyle medicine. Carrie’s clinical focus bridges conventional psychiatry with holistic strategies to support mental health through nutrition, physiology, and sustainable lifestyle interventions. Her professional writing explores topics such as functional medicine, autism, provider well-being, and medical ethics.